New Medicine, Inc. FUTURE ONCOLOGY

GENE THERAPY OF CANCER-PART II
MECHANISM-BASED AND OTHER
TREATMENT OPTIONS FROM
THE 9TH INTERNATIONAL CONFERENCE
ON GENE THERAPY OF CANCER,
SPONSORED BY SIDNEY KIMMEL CANCER CENTER,
SAN DIEGO, CA, DECEMBER 7-9, 2000

Tumor Suppressor Compensation/Enhancement/Targeting

p53

Replacement of a defective p53 gene
Cytolytic agents targeting p53-deficient cancer cells

mda-7

pHyde

p27

Inhibition/Knock-Out of Promoters of Tumor Growth

Sex hormone-binding globulin (SHBG)
T-ag of Human Polyomavirus BK (BKV)
K-ras

Growth Factor Suppression

Transforming growth factors (TGF)

Antiangiogenic Gene Therapy

In vivo Delivery and Expression of Endostatin
Tumor Suppressor Activity and Inhibition of Angiogenesis

Suicide Gene-based Approaches

Gene-directed Enzyme Prodrug Therapy (GDEPT)
- HSVtk/ganciclovir
- Cytosine deaminase/5-fluorocytosine (CD/5-FC)
- Cytochrome P450/cyclophosphamide (CYP/CP)
- Horseradish peroxidase/indole-3-acetic acid (HRP/IAA)
- Carboxylesterase/irinotecan (CE/CPT-11)
- Methioninase/selenomethionine (METase/SeMET)
- Beta-glucuronidase/HMR 1826
Self-Deleting Vectors

Other Direct Cytotoxicity Approaches

Transfer of Genes Encoding Viral Fusogenic Membrane Glycoproteins
Tumor-specific Activation of dsRNA-dependent PKR
Attenuated, Replication-competent Adenoviruses

Potentiation of Conventional Therapy

Chemotherapy Sensitization
Radiation Therapy Sensitization
Combined Chemo/Radiotherapy Sensitization
Protection of Critical Host Tissues

Cell Marking Studies

FUTURE ONCOLOGY
Volume 6 #6/7 July 15, 2001

State-of-the-Art in the Management of Cancer

Meeting Coverage

FUTURE ONCOLOGY Volume 6 #6/7 July 15, 2001

State-of-the-Art in the Management of Cancer

Meeting Coverage

FUTURE ONCOLOGY
Volume 6 #6/7 July 15, 2001